Opiate Dependence
5
Pipeline Programs
1
Companies
5
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
3
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
AlkermesDUBLIN 4, Ireland
5 programs2
3
Extended-Release NaltrexonePhase 31 trial
Medisorb naltrexone 380 mgPhase 31 trial
VIVITROL® 380 mgPhase 31 trial
Medisorb naltrexone 75 mgPhase 21 trial
very low dose naltrexonePhase 21 trial
Active Trials
+2 more trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
AlkermesExtended-Release Naltrexone
AlkermesMedisorb naltrexone 380 mg
AlkermesVIVITROL® 380 mg
Alkermesvery low dose naltrexone
AlkermesMedisorb naltrexone 75 mg
Clinical Trials (5)
Extended-Release Naltrexone for Opioid Relapse Prevention Following Release From Jail
Start: May 2010Est. completion: Jul 2013
Phase 3Completed
ALK21-021: A Safety Study of Medisorb® Naltrexone (VIVITROL®) Administered to Health Care Professionals
Start: Mar 2009Est. completion: May 2012
Phase 3Completed
ALK21-013: Efficacy and Safety of Medisorb® Naltrexone (VIVITROL®) in Adults With Opioid Dependence
Start: Jun 2008Est. completion: Nov 2010
Phase 3Completed
Low Dose Naltrexone-buprenorphine Transfer to Vivitrol Injection in Opioid Dependence
Start: Sep 2012Est. completion: Feb 2015
Phase 2Completed
ALK21-004: Single-dose Opiate Challenge of Medisorb® Naltrexone (VIVITROL®) in Adults Who Use Opioids
Start: Mar 2002Est. completion: May 2003
Phase 2Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
3 late-stage (Phase 3) programs — potential near-term approvals
1 companies competing in this space